A detailed history of High Tower Advisors, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, High Tower Advisors, LLC holds 20,150 shares of BCRX stock, worth $159,588. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,150
Previous 18,150 11.02%
Holding current value
$159,588
Previous $92,000 34.78%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.13 - $6.79 $8,260 - $13,580
2,000 Added 11.02%
20,150 $124,000
Q4 2023

Feb 12, 2024

BUY
$4.98 - $6.77 $1,000 - $1,360
201 Added 1.12%
18,150 $108,000
Q3 2023

Nov 08, 2023

SELL
$6.71 - $7.92 $4,368 - $5,155
-651 Reduced 3.5%
17,949 $127,000
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $129,456 - $163,866
18,600 New
18,600 $130,000
Q1 2021

May 10, 2021

SELL
$7.37 - $13.61 $189,600 - $350,130
-25,726 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$3.37 - $8.61 $86,696 - $221,500
25,726 New
25,726 $191,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.47B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.